대한뉴팜

In accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and the [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], a reevaluation was conducted for [7 vitamin therapeutic groups, 367 products] and [7 tonic therapeutic groups, 900 products] with results hereby announced. Affected products include:Placein M Injection (Human Placenta Extract)Calibin Soft Capsules (Calcitriol)For inquiries regarding this notice: Responsible Department: Daehan New Pharm R&D Division Contact: 02-3415-7857

Daehan New Pharm Co., Ltd. Launches "Citracal F/D Tablets"Improved Calcium Bioavailability... Minimizes Side Effects Such as Gastrointestinal Disorders Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has released ETC-type "Citracal F Tablets" and OTC-type "Citracal D Tablets," calcium supplements combining calcium citrate and vitamin D3. Citracal F/D Tablets, combining calcium citrate and vitamin D3, have improved absorption rate and calcium bioavailability by over 30% compared to conventional calcium carbonate or oyster shell powder. Unlike calcium carbonate supplements, they do not produce gas in the intestines, minimizing side effects such as gastrointestinal discomfort, constipation, and kidney stone formation. Particularly, Citracal F Tablets are covered by insurance and improve patient adherence with a once-daily dosage. Daehan New Pharm Co., Ltd. aims to expand sales by dual marketing strategies using Citracal F Tablets for ETC prescriptions and Citracal D Tablets for OTC pharmacy sales.

Daehan New Pharm Holds Opening Ceremony and New Product Launch Ceremony Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held its opening ceremony and new product launch on January 2-3 at the Rabidol Resort with all employees in attendance under the slogan “Healthy Life, Disease-Free Society, A Company Sharing Warmth.” During the opening ceremony, New Year’s greetings were exchanged and awards were presented to seven exemplary employees. CEO Park Myung-rae, in his New Year’s speech, praised the employees for achieving last year’s sales target of 50 billion KRW and emphasized three key focus areas for leap-forward development as a top-tier pharmaceutical company: continuous management innovation, sharing awareness and voluntary participation among members, and creating added value individually. Following the opening ceremony, the new product launch featured Citracal F Tablets (ETC) and D Tablets (OTC), which enhance bioavailability by over 30% compared to existing calcium supplements while significantly reducing side effects. The entire staff renewed their commitment to the successful launch and growth of these key products. A special lecture on “Time Management” was delivered by Dr. Song Hyuk-kwan, director of the Paradigm Research Institute, reinforcing efficient work management. Later, Mr. Lee Sang-yong, known for his social service efforts including heart surgery for children, spoke about the social responsibility of pharmaceutical companies, inspiring attendees to reflect on the company’s role in society.

Daehan New Pharm received the $3 Million Export Trophy at the 42nd Trade Day event held on the 31st. This achievement came 7 years after the company's first export to Vietnam in 1999 and 3 years after receiving the $1 Million Export Trophy in 2002. Daehan New Pharm exports primarily cephalosporin pharmaceuticals to over 20 countries including Vietnam, Pakistan, and Cuba. Recently, exports of thrombolytic agent streptokinase and anticancer drugs have also significantly increased, and this year the company entered the pharmaceutical markets in Azerbaijan and Nigeria. A company spokesperson said, 'Receiving the $3 Million Export Trophy signifies that the excellence in quality has been highly recognized overseas,' and added, 'We will continue to strive to achieve $5 million and $10 million export milestones.' Daehan New Pharm plans to maintain continuous efforts towards export growth by expanding overseas partnerships and fostering export strategies for marketable products.Source: Money Today, Reporter Choi Jeong-ho

On the 28th, Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) announced that it had delivered medical supplies valued at approximately 15 million KRW to the Zaytun Unit deployed in Iraq. Brigade Commander Lim Guk-sun of the Zaytun Unit expressed gratitude for the support and stated, "The medical supplies will mainly be used for civil service activities in about 20 villages in the area where the unit is stationed in Iraq."

[Notice] Based on the Ministry of Food and Drug Safety Pharmaceutical Management Team-12079 (’05.11.18), the unified adjustment plan regarding the approval details (precautions for use) for fluoxetine hydrochloride single formulation (oral) and, based on the Ministry of Food and Drug Safety Narcotics Management Team-15069 (’05.11.18), the unified adjustment plan regarding approval details (indications, dosage and administration, precautions for use) for psychotropic anorectic agent phentermine hydrochloride formulation are as follows. Affected products include:Depren Capsules (Fluoxetine Hydrochloride)Melcapt Tablets (Mercaptopurine)Festy Tablets (Phentermine Hydrochloride) For inquiries related to this notice: Responsible Department: Daehan New Pharm Development Division Contact: 02-3415-7857

On the 20th, Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held a celebration at the company’s main auditorium with all employees in attendance to mark its 21st anniversary. The event included an awards ceremony for six employees with 20 and 10 years of long-term service, a congratulatory speech, and a ceremonial rice cake cutting. Chairman Lee Wan-jin, in his address, emphasized the company’s dignity and pride as it reached adulthood in the 21st century and urged the completion of mid- to long-term development plans to achieve the greatest accomplishments in company history. He laid out key future management directives for creating a new future: (1) focusing core competencies on profitability improvement, (2) elevating all employees’ energy into a growth engine, and (3) dedicating efforts to self-development and R&D. He also expressed hope that the anniversary celebration would be a meaningful occasion for all employees to renew their commitment to transformation and leap-forward growth. During the event, Assistant Manager Yoon Young-sun of the Factory Management Team was awarded for 20 years of service and received a prize of 20 don of gold, while Assistant Manager Oh Seok-gyun of the Bio Team and four others received 10-year service awards with 10 don of gold. In addition, 33 outstanding employees were granted overseas training opportunities in Southeast Asia as awards.

Daehan New Pharm Practices 'V-3 UP' for Achieving GoalsSix-Hour Climb to Biro Peak on Odaesan Mountain... Awards Ceremony for 33 Outstanding Employees Held Daehan New Pharm (CEO Park Myung-rae) held the 'ATAT 2005 (Achieving Target All Together)' seminar and hiking event over two days on the 7th and 8th, with all employees participating to strengthen commitment to goal achievement, establish goal awareness, and activate sales. On the first day, the hike course started from Sangwonsa Temple on Odaesan Mountain and circled Biro Peak, with everyone completing the approximately 6-hour journey without incident. The evening gathering fostered team unity and was a lively affirmation of organizational strength. On the second day, an in-depth discussion on the strategies of each business unit for achieving goals in the second half of 2005 was held during the 'ATAT 2005 Achievement Seminar' aimed at leaping forward as a top-tier company. Based on the slogan "Let's Achieve Our Goals Together," the detailed execution goals of 'V-3 UP' (Volume up: achieving goals, Value up: creating value, Vision up: creating the future) were set to strengthen unity among all employees. This marked a spirited leap toward successful completion of 2005 and a fresh start for 2006. The event also included an awards ceremony for 33 outstanding employees, granted overseas training opportunities in Southeast Asia, and a special lecture titled "The Difference Between Professionals and Amateurs" delivered by lightning courier instructor Jo Tae-hoon emphasizing professional spirit.

In accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], reevaluation was conducted on [2 therapeutic groups of artificial perfusion agents, 22 sites, 141 items] and [4 other metabolic therapeutic groups, 55 sites, 848 items], and the results are hereby announced. Affected products include:Glizide Tablets (Gliclazide)Daien Capsules (Green Tea Powder, Ortho-Ciphen Powder)Bronase Tablets (Deoxyribonuclease, Bromelain) For inquiries related to this announcement: Responsible Department: Daehan New Pharm Development Division Contact: 02-3415-7857